Filing Details
- Accession Number:
- 0001209191-23-044534
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-03 18:03:20
- Reporting Period:
- 2023-08-01
- Accepted Time:
- 2023-08-03 18:03:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1671858 | Ars Pharmaceuticals Inc. | SPRY | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1551891 | Laura Shawver | C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-08-01 | 18,715 | $1.27 | 229,061 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-01 | 18,715 | $7.19 | 210,346 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-08-02 | 36,281 | $1.27 | 246,627 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-02 | 36,281 | $7.09 | 210,346 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-01 | 18,715 | $0.00 | 18,715 | $1.27 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-02 | 36,281 | $0.00 | 36,281 | $1.27 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 84,282 | 2030-04-28 | No | 4 | M | Direct | |
| 48,001 | 2030-04-28 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.11 to $7.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.95 to $7.23, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
- Immediately exercisable.
Billionaire Hedge Funds
